BriaCell to Present Clinical Data at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting May 29
March 31 2020 - 6:30AM
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, announces that it has been selected to present at the 2020
ASCO Annual Meeting, a virtual event held during the dates of the
originally planned in-person Annual Meeting (May 29-June 2, 2020).
The ASCO Annual Meeting represents the world’s largest gathering of
oncology physicians, biotechnology executives, researchers, and
investment analysts to discuss cutting-edge clinical research and
therapeutics in oncology.
Dr. Bill Williams, BriaCell’s President &
CEO, and Dr. Charles Wiseman, BriaCell’s Scientific Founder and
Director, will present clinical data and pathological findings from
the Phase I/IIa studies of Bria-IMT™ alone or in combination with
checkpoint inhibitors in advanced breast cancer patients.
The details of BriaCell’s ASCO poster are as
follows:
Abstract Title: Breast cancer
grade and clinical benefit in patients with advanced breast cancer
treated with an engineered whole tumor cell-targeted immunotherapy
alone or in combination with checkpoint inhibition.Session
Title: Developmental Therapeutics—Immunotherapy
Session Type: Poster
SessionDate: Friday, May 29, 2020
Time: 8:00 AM - 11:00 AM CST
Location: Virtual meetingTemporary
Abstract Submission ID: 306433Abstract Number for
Publication: 3033Poster Board
#: 97Role
Responsibilities: PresenterPrimary
Track: Developmental
Therapeutics—Immunotherapy
Following the presentation, a copy of the poster
will be posted
on https://briacell.com/novel-technology/scientific-publications/.
“We are excited to be invited to present data on
BriaCell’s lead candidate, Bria-IMT™. We believe that Bria-IMT™ has
a unique mechanism of action that allows it to work with various
immunotherapies, including checkpoint inhibitors, to improve the
body's anti-tumor response and potentially offer clinical benefits
in patients with advanced breast cancer,” said Dr.
Williams.About American Society of Clinical Oncology (ASCO)
Conference
Founded in 1964, ASCO is the world’s leading
professional organization for physicians, oncology professionals,
and research scientists in the field of oncology. ASCO’s Mission
over the years has been to conquering cancer through research,
education, and promotion of the highest quality patient care.
ASCO’s Annual meeting represents the world’s
largest gathering of oncology physicians, biotechnology executives,
researchers, patient advocates, and investment analysts to discuss
cutting-edge clinical research and therapeutics in oncology, and to
gain insights for improving cancer care.
For additional information on the 2020 ASCO’s
Annual meeting, please visit https://www.asco.org/.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding
Forward-Looking Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to
known and unknown risks relevant to the Company in particular
and to the biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024